Ostarine - Lenvima (Lenvatinib) Interaction

Interaction Details

Lenvatinib is classified as belonging to the following category: Hepatotoxic Drugs

Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Some clinical research shows that ostarine can increase alanine aminotransferase, a marker of liver damage, in some patients. Additionally, the U.S. Food and Drug Administration warns that supplements containing SARMs, such as ostarine, have been associated with reports of liver toxicity and there is at least one report of drug-induced liver injury in a 40-year-old male which was attributed to the use of ostarine for 2 months.

Interaction Rating

Likelihood of Occurrence

Interaction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists

References

• Warning Letter: Ironmag Labs 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm582464.htm Accessed: November 1, 2017
• Warning Letter: Panther Sports Nutrition 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm581630.htm. Accessed: November 1, 2017
• Warning Letter: Infantry Labs LLC 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm582685.htm. Accessed: November 1, 2017
• Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 2013;14(4):335-45.
• Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II tri
• Bedi H, Hammond C, Sanders D, Yang HM, Yoshida EM. Drug-induced liver injury from enobosarm (ostarine), a selective androgen receptor modulator. ACG Case Rep J 2021;8(1):e00518.

Lenvatinib Overview

• Lenvatinib is used to treat a certain type of thyroid cancer that has returned or that has spread to other parts of the body and cannot be treated with radioactive iodine. Lenvatinib is also used along with everolimus (Afinitor, Zortress) to treat renal cell carcinoma (RCC, a type of cancer that begins in the kidney) in people who have previously received treatment with another chemotherapy medication. Lenvatinib is also used along with pembrolizumab (Keytruda) as an initial treatment for advanced renal cell carcinoma. Lenvatinib is also used to treat hepatocellular carcinoma (HCC; a type of liver cancer) that cannot be treated with surgery. Lenvatinib is also used along with pembrolizumab (Keytruda) to treat a certain type of cancer of the endometrium (lining of the uterus) that has spread to other parts of the body or worsened during or after treatment with chemotherapy medications or that cannot be treated with surgery or radiation therapy. Lenvatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.

Ostarine - More Interactions

Ostarine interacts with 578 drugs

Interaction Rating Key

These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.